drugset / Trial / NCT04599777
TACE Combined With Sorafenib and Tislelizumab for Advanced HCC
NaSingle-groupOpen-labelTreatment
Summary
This study will evaluate the efficacy and safety of transcatheter arterial chemoembolization (TACE) combined with sorafenib and tislelizumab in patients with advanced hepatocellullar carcinoma (HCC).
Timeline
- Start
- 2020-10-01
- Primary completion
- 2022-10-11
- Completion
- 2022-10-11
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Sorafenib | Small molecule | 400 mg | Oral |
| Subject | Tislelizumab | Monoclonal antibody | 200 mg | Intravenous |